norfluoxetine has been researched along with Long QT Syndrome in 1 studies
norfluoxetine: metabolite of fluoxetine; RN given refers to parent cpd without isomeric designation
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
Excerpt | Relevance | Reference |
---|---|---|
"Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 5.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
"Fluoxetine (Prozac) is a widely prescribed drug in adults and children, and it has an active metabolite, norfluoxetine, with a prolonged elimination time." | 1.33 | Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. ( Anderson, CL; Anson, BD; Delisle, BP; Eckhardt, LL; Gillman, BM; Holzem, KM; January, CT; Klemens, CA; Makielski, JC; Rajamani, S; Valdivia, CR, 2006) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Rajamani, S | 1 |
Eckhardt, LL | 1 |
Valdivia, CR | 1 |
Klemens, CA | 1 |
Gillman, BM | 1 |
Anderson, CL | 1 |
Holzem, KM | 1 |
Delisle, BP | 1 |
Anson, BD | 1 |
Makielski, JC | 1 |
January, CT | 1 |
1 other study available for norfluoxetine and Long QT Syndrome
Article | Year |
---|---|
Drug-induced long QT syndrome: hERG K+ channel block and disruption of protein trafficking by fluoxetine and norfluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Blotting, Western; Cell Line; Cell Membrane; Cisapr | 2006 |